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ABSTRACT

Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved
chemotherapeutic agent that is used for the treatment of testicular cancer. According to
previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC)
and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic
forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To
minimize its toxicity, we have developed an orally delivered nanoscale drug delivery
system by which Mit-A can be delivered using biocompatible and biodegradable
materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the
inner core and chitosan (CS) on the outer shell of nanoparticles having an average size
of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel
which release the payload at the colonic site to target CRC and CSCs thus, contributing
to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A
nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor
burden in an orthotopic CRC mouse model. Taken together, an orally administered
nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a
promising drug delivery system to target CRC and CSCs with reduced toxicity.
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CHAPTER 1: INTRODUCTION

1.1 Colorectal cancer
Colorectal cancer (CRC) usually transforms from normal colonic epithelium to
polyps in walls of the colon or rectum and finally to invasive form of cancer [1]. This
transformation involves numerous gene mutations but mostly appears in tumorsuppressing genes and DNA repair mechanisms which leads to invasion,
proliferation, and metastasis of cancer [1, 2]. CRC is the second common cause of
cancer in both men and women and the second most common cause of cancerrelated deaths in the USA [3]. American cancer society estimates 104,610 new
cases and 53,200 deaths due to colorectal cancer in both males and females
combined in the year 2020 with a lifetime estimated risk of 5%. Despite the
advancement in diagnosis and treatment, the disease-free survival remains poor in
CRC patients [4]. Particularly the patients diagnosed with metastatic stage IV CRC
have a five-year survival rate of just 14% [5]. The metastatic and the re-emergence
of CRC are the major challenges in the management of CRC. The recurrence and
the metastatic form of CRC are related to the presence of CSCs in the tumor [6].
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1.2 Cancer Stem Cells
Cancer stem cells (CSCs) are a very small population in the tumor cells and can
self-renew, proliferate and differentiate into a variety of cells that contribute to the
tumor mass. CSCs are responsible for tumorigenesis, invasion, metastasis and drug
resistance in CRC and are usually developed due to genetic modifications in intestinal
stem cells which are adequate to trigger malignant transformation [4]. Therefore,
targeting CSCs with the other tumor cells in the CRC will drastically improve the overall
survival rate in patients diagnosed with advanced metastatic CRC.

1.3 Current Treatment for Colorectal Cancer
The current treatment options available for CRC are radiotherapy, chemotherapy,
and immunotherapy which reduces the tumor mass by aiming to kill the tumor cells by
directly targeting them or elevating the body’s natural immune system. They often fail
to target CSCs which are responsible for the highly aggressive and invasive form of
CRC post-treatment [5]. Out of total CRC cases, 40%-70% of the patients have a
recurrence after initial treatment [7]. The inhibition of self-renewal and differentiation
properties of CSCs are the current strategies used to target CSCs. Therefore, finding
a therapeutic option that will be anti-CSCs in addition to anti-cancer will be an effective
strategy to treat patients with advanced metastatic CRC.

1.4 Mithramycin-A
Mithramycin - A (Mit-A) is a polyketide antibiotic which is FDA approved drug for
testicular carcinoma and a potential CSCs targeting chemotherapeutic agents [5]. Mit2

A inhibits transcription factor by binding to the minor groove of DNA. Studies have
shown that Mit-A suppresses CRC by targeting tumor cells and the CSCs present in
the tumor bulk [5]. The mechanism for inhibition of CSCs is related to blocking of
specificity protein-1 (SP1) binding to transcription factor by Mit-A. SP1 is
overexpressed in CRC which regulates numerous genes that are responsible for cell
differentiation, proliferation, apoptosis, response to DNA damage, chemoresistance,
and metastasis [5, 8]. Overall, Mit-A is known to induce apoptosis in CSCs and other
tumor cells in CRC and inhibits SP1 transcription factor, which in turn inhibits the
growth of CSCs [5]. Mit-A when used as an anti-neoplastic chemotherapeutic agent,
is administered intravenously to attain maximum bioavailability but has systemic
toxicity and is known to cause hepatic dysfunction, damage to tubular cells, decreased
serum calcium level and gastrointestinal bleeding [8, 9]. To achieve the maximum
effect there is a need to formulate Mit-A into drug delivery system for targeted delivery
to limit systemic circulation and thereby reduce toxicity. We plan to use
nanotechnology based approach, which has shown to deliver chemotherapeutic
agents in a very efficient manner due to its unique features in drug delivery
applications [10-12].

1.5 Novel Therapeutic Approach
The most widely used and most popular method of drug administration is oral route
due to its ease of administration, avoiding metabolism of the drug in the liver, high
patient compliance, non-invasive and flexibility in the design of dosage form [13-15].
Some of the parameters to be considered while formulation and delivering Mit-A via
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oral administration is the hydrophobic nature of the drug, complex gastrointestinal
environment, and tumor targeting in the colon. Recent advancements in
nanotechnology can overcome the barrier of solubility and toxicity by formulating MitA nanoparticles using biocompatible and biodegradable polymers which has the
potential to enhance permeability through the intestinal barrier. Nanoparticles are
known to passively target tumor mass by enhanced permeability and retention (EPR)
effect which gets permeated and accumulated in the leaky tumor vasculature after
entering it and retaining in tumor mass due to poor lymphatic drainage [8, 11]. Due to
high prevalence and longer duration of treatment colon targeted oral drug delivery of
Mit-A would be significantly beneficial.

1.6 Hypothesis and Specific Amis
Oral drug delivery of Mit-A nanoparticles using alginate/chitosan hydrogel will
target colorectal cancer. The first aim of this project is to synthesize and characterize
Mit-A nanoparticles using biodegradable and biocompatible materials and the second
aim is to test whether orally delivered Mit-A nanoparticles in alginate/chitosan hydrogel
can target colorectal cancer for site-specific delivery in the colon.
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CHAPTER 2: METHODS AND MATERIALS

2.1 Materials
Poly(D,L-lactide-co-glycolide) acid (PLGA)(Lactide:Glycolide = 50:50, Mw: 30-60
kDa) and polyvinyl alcohol (PVA) (Mw: 31 kDa) was purchased from Sigma Aldrich,
USA. glacial acetic acid, dichloromethane (DCM), ethyl acetate (EtOAc), DiR’ (1,1'Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide) and sodium alginate was
purchased from Fischer Scientific, USA. Water-soluble, low molecular weight chitosan
(CS) (Mw:10kDa) was used. Mit-A (Mw: 1085.2 Da) was purchased from Cayman
Chemical, USA. Cyanine 5.5 (Cy5.5) NHS ester dye was purchased from
luminoprobe. PLGA and CS are US FDA approved, biocompatible and biodegradable
materials [16, 17]. Alginate is a US FDA approved polysaccharide, biocompatible and
has the chelating ability [18, 19].

2.2 Preparation of Mithramycin-A nanoparticles
Mit-A nanoparticles were prepared by a single emulsion solvent evaporation
method. Briefly, PLGA which was dissolved in dichloromethane (DCM) at a
concentration of 100 mg/mL. 2 mg of Mit-A was dissolved in EtOAc to get a
concentration of 1 mg/mL with a weight ratio of 1:50 to the polymers and then mixed
to constitute 3 mL organic phase of the emulsion. PVA solution (5%) with CS solution
(0.5%) was prepared in dilute glacial acetic acid solution (0.1%) to form the aqueous
5

phase of the emulsion. The oil phase was then added to 4 mL of PVA (5%)-CS (0.5%)
solution under stirring conditions and was probe sonicated for 10s seconds each time
for 10 times. This emulsion was immediately poured to 12.5 mL of PVA (0.3%) with
CS (0.03%) in aqueous acidic solution and was stirred constantly overnight to
evaporate organic solvent. The nanoparticles formed by this method were collected
by centrifugation at 13,000 RPM for 20 minutes, washed two times with nano-pure
water and resuspended in 3 mL nano-pure water. The aqueous solution of the
nanoparticles was then lyophilized using a freeze dryer and dried nanoparticles were
stored at 4°C in the airtight container until further use. Blank nanoparticles, Cy5.5
labeled nanoparticles and DiR nanoparticles were prepared using a similar procedure.
The schematic illustration of nanoparticles and their method of preparation is shown
in Figure 1.
2.3 Particle size, Zeta potential, and Morphology
The mean particle size and zeta potential of the prepared nanoparticles were
measured in nano-pure water at by dynamic light scattering at 25°C using zetasizer
(Malvern Panalytics, United Kingdom). The morphology of Mit-A nanoparticles was
examined by transmission electron microscopy. The sample for TEM was diluted
1:100 from the 3 mL stock before the nanoparticles were subjected to freeze-drying
and placed on a copper grid and let it dry overnight.
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Figure 1: Schematic illustration of nanoparticles. (A) Overview of preparation of Mit-A
nanoparticles. Illustration of (B) Mit-A nanoparticles, (C) Blank nanoparticles, (D) Cy5.5 labeled
nanoparticles, and (E) DiR nanoparticles.
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2.4 Drug loading (DL) and Encapsulation Efficiency (EE)
The EE of Mit-A nanoparticles was calculated using the supernatant from the
washing of the nanoparticles to indirectly calculate the amount of Mit-A presents
encapsulated in the particles. The standard curve of Mit-A from concentration 0.5 0.0078 mg/mL was plotted at 410 nm by UV spectrometer and unknown concentration
from the supernatant was calculated with the formula:
Encapsulation efficiency(EE%) =

𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐄𝐧𝐭𝐫𝐚𝐩𝐞𝐝 𝐌𝐢𝐭 𝐀 𝐢𝐧 𝐍𝐏𝐬
𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐌𝐢𝐭 𝐀 𝐮𝐬𝐞𝐝

X 100

The DL was calculated by freeze-drying the nanoparticles solution and then weighing
the solid nanoparticles obtained and was calculated using formula:
Drug loading(DL%) =

𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐄𝐧𝐭𝐫𝐚𝐩𝐞𝐝 𝐌𝐢𝐭 𝐀 𝐢𝐧 𝐍𝐏𝐬
𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐌𝐢𝐭 𝐀 𝐍𝐏𝐬

X 100

2.5 In-vitro drug release profiles
For the in-vitro release study of Mit-A was carried out at pH 7.4 and pH 5.5, 300
µg of Mit-A containing nanoparticles were added into a dialysis bag of 2000 molecular
weight cut off which released Mit-A in 10mL of PBS with 0.2% tween 80 (pH 7.4 and
pH 5.5). The PBS with 0.2% tween 80 was stirred at 300 rpm at 37°C. At designated
time intervals, 500 uL of the solution outside the dialysis bag was extracted and then
the same volume of fresh PBS with 0.2% tween 80 was replaced. The drug
concentration in the solution was measured by UV at 410 nm and release was
reported.

8

2.6 In-vitro cytotoxicity
MC38 is a mouse colon carcinoma cell line that was cultured in Dulbecco's
Modified Eagle Medium (DMEM) with 10% fetal bovine serum, 1% PenicillinStreptomycin (10,000 U/mL), 1% sodium pyruvate (100nM) and 1% non-essential
amino acids (100X). MC38 cells (2000 cells/well) were cultured on 96 well plate for 1
day and treated with varying concentrations of Mit-A nanoparticles and Mit-A free drug
and equivalent amount of polymer used in Mit-A nanoparticles by treating it with blank
nanoparticles for 48- and 72- hours, respectively. Cell viability was assayed after 48hours and 72- hours post-treatment with CellTiter-Glo (Promega) and percent cell
viability was plotted using GraphPad Prism.

2.7 Oral delivery of nanoparticles
Cy5.5 labeled chitosan nanoparticles were used to deliver it to the colon with
alginate/chitosan double crosslinked hydrogel. The hydrogel was prepared by mixing
sodium alginate and chitosan solution of 7 g/L and 3 g/L respectively and then mixing
it in the ratio 1:1 for 24 hours [10, 14, 20]. The Cy5.5 nanoparticles were then
dispersed in resultant solution thoroughly to orally gavage the mice. To crosslink the
hydrogel a chelating solution containing 30 mmol/L of sodium sulfate and 70 mmol/L
of calcium chloride was prepared. Cy5.5 nanoparticles were administered orally by
gavaging to the Nu/Nu nude mice with a dose of 0.5 mg/kg in 200 uL of
alginate/chitosan solution. Oral gavage of 50 uL of the chelating solution was then
administered to crosslink the alginate/chitosan solution by calcium and sulfate ions
present in the chelating solution. The control group was administered with blank
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nanoparticles dispersed in the hydrogel. After oral gavage, the mice were imaged in
an in-vivo imaging system (IVIS) at different time intervals to track the movement of
Cy5.5 nanoparticles which emit fluorescence at excitation and an emission
wavelength of 678 nm and 694 nm respectively.

2.8 In-vivo evaluation for drug release
DiR encapsulated nanoparticles were used to deliver it to the colon with
alginate/chitosan double crosslinked hydrogel. The hydrogel was prepared,
nanoparticles were dispersed and delivered in the same way as Cy5.5 nanoparticles
in the hydrogel to Nu/Nu nude mice. The control group was administered with just DiR
nanoparticles without the hydrogel. The dose of DiR nanoparticles was 0.5 mg/kg and
the mice were imaged at different time points in IVIS. The organs from these mice
were extracted for ex-vivo images and fluorescence was recorded for biodistribution
of nanoparticles at excitation and an emission wavelength of 748 nm and 780 nm,
respectively.

2.9 In-vivo therapeutic effect
The orthotopic colon cancer mouse model was developed by injecting 200,000
MC38 cells in the wall of the cecum of C57BL/6 mice on day 0. The treatment was
initiated on day 6 by orally gavage of Mit-A nanoparticles in 200 uL of alginate/chitosan
solution prepared by mixing in 1:1 ratio of 7 g/L of alginate solution and 3 g/L of
chitosan solution followed by 50 uL of the chelating solution. The dose of Mit-A was 1
mg/kg and the equivalent amount of polymer was gavaged using blank nanoparticles.
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The treatment was terminated on day 18 and the mice were weighted sacrificed, and
the tumor was extracted on day 20. The outline of the experimental design has been
shown in figure 2.

Figure 2

Figure 2: Schematic of animal experimental design

2.10 Statistical Analysis
All the obtained quantitative data was analyzed using GraphPad Prism or MS
Excel by mean and ± Standard Error Mean (S.E.M) and p-value of < 0.05 was
considered to be statistically significant.
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CHAPTER 3: RESULTS AND DISCUSSIONS

3.1 In-vitro characteristics of nanoparticles
Table 1 shows the Z-average size, poly dispersity index (PDI) and zeta potential
of the 3 batches of Mit-A nanoparticles. The average size of three batches of Mit-A
nanoparticles were found to be 166.66 ± 0.86 nm and PDI was 0.063 ± 0.012 with
average zeta potential 4.14 ±1.13 mV. The positive zeta potential indicates the
presence of chitosan on the outermost layer of the nanoparticles. Table 2 represents
the %EE and %DL of three batches of Mit-A nanoparticles and the average of three
batches of Mit-A nanoparticles were found to be 30.42 ± 0.59% and 0.9 ± 0.1%
respectively. The size was confirmed by TEM as shown in Figure 3.
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Figure 3

146nm
168nm

138nm

Figure 3: TEM images of Mit-A nanoparticles

3.2 In-vitro drug release
In vitro Mit-A release from nanoparticles was investigated at pH 7.4 and pH 5.5 in
PBS with 0.2% tween 80 at 37°C. As shown in Figure 4, a relatively fast release of
Mit-A from nanoparticles was observed at pH 5.5 than pH 7.4. The tumor
microenvironment is more acidic [21] than the normal physiological pH and so, faster
drug release at acidic pH would be beneficial as it would release the drug faster. MitA nanoparticles exhibited slow release with the 100% release in 30 hours in PBS with
0.2% tween 80. There was no burst release observed at the initial time points at both
pH 5.5 and pH 7.4.
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Figure 4: Mit-A drug release from nanoparticles at pH 7.4 and
pH 5.5.

3.3 In-vitro cytotoxicity assay
In this study, the IC50 of Mit-A nanoparticles was compared with that of free Mit-A
using MC-38 cells. From the Figure 5(A) and 5(C), we can conclude that at 48- and
72- hours the IC50 of the Mit-A nanoparticles was found to be 2.979 µg/mL and 1.519
µg/mL and is slightly higher to Mit-A free drug that is 1.052 µg/mL and 0.5023 µg/mL
respectively. The reason of IC50 not exact same can be explained due to slow release
of the drug in-vitro. The amount of polymer used for Mit-A nanoparticles same amount
of the polymer was used to assess the cytotoxicity of biomaterials by using blank
nanoparticles. The IC50 of blank nanoparticles for 48- hours was 671.187 µg/mL and
for 72- hours was 416.177 µg/mL and is much higher than the Mit-A nanoparticles
which suggest that biomaterials in the nanoparticles are not toxic by itself and the Mit-
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A in the nanoparticles is responsible for cell death of MC38 colon cancer cell line as
shown in Figure 5(B) and 5(D) at 48- and 72- hours, respectively.

Figure 5: MC-38 cells (2000/well) were cultured on 96 well plate for 1 day and treated
with varying concentrations of (A) Mit-A nanoparticles and Mit-A free drug for 48 hours
(B) Mit-A nanoparticles and equivalent amount of blank nanoparticles for 48 hours. Cell
viability was assayed after 48 hours post treatment by CellTiter-Glo (Promega). Percent
cell viability was plotted using GraphPad Prism. MC-38 cells were cultured on 96 well
plate for 1 day and treated with varying concentrations of (C) Mit-A nanoparticles and
Mit-A free drug for 72 hours (D) Mit-A nanoparticles and equivalent amount of blank
nanoparticles for 72 hours. Cell viability was assayed after 48 hours post treatment by
CellTiter-Glo (Promega). Percent cell viability was plotted using GraphPad Prism.

3.4 Colon targeted delivery of nanoparticles
To evaluate the integrity of hydrogel at gastric pH, Cy5.5 labelled nanoparticles
were tracked and signals were seen in the lower part of the mouse gastrointestinal
tract when imaged in IVIS at 3 hours and 6 hours, respectively as shown in Figure 6.
This suggests that the alginate/chitosan hydrogel remains intact at gastric pH and the
nanoparticles deliver the payload at the intended site in the colonic region. The
hydrogel swells at the basic pH and swells to its extremity at cecum and colon and
15

tends to release the encapsulated nanoparticles for its required therapeutic activity
[14, 20, 22].
Figure 6

Figure 6: IVIS images of mice orally gavaged with blank nanoparticles dispersed in
hydrogel (control) and Cy5.5 labelled nanoparticless dispersed in hydrogel on the right of
each image. (A) Image was captured at 3 hours time point after oral gavage, and (B)
Image captured at 6 hour time point after oral gavage. The signals recorded are in
Radiance Efficiency.

3.5 In-vivo evaluation for drug release
To mimic the drug release of Mit-A from nanoparticles, DiR encapsulated
nanoparticles were dispersed in the hydrogel and were orally gavaged to the Nu/Nu
nude mice. The control group was administered with DiR nanoparticles without
hydrogel. Figure 7 shows that DiR nanoparticles administered orally with hydrogel
targets colon and cecum which again suggests that nanoparticles payload can be
delivered successfully by the hydrogel. The DiR nanoparticles delivered in hydrogel
can be seen in the colon till 6 hours and nanoparticles delivered without hydrogel is
directly excreted from the body without being retained in the colon or cecum of the
mouse.
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Figure 7
C

B

D

A

E

F

G

Figure 7: IVIS images of mice (A) Control group(left) administered with DiR nanoparticles
without hydrogel and experiment group (Right) administered with DiR nanoparticless with
hydrogel. (B, C, D) Ex-vivo images of mouse administered with DiR nanoparticles with hydrogel
showing presence of DiR in the colon and cecum at 6 hours time point. (E, F, G) Ex-vivo images
of control group administered with just DiR nanoparticles without hydrogel shows no presence
of DiR in colon and cecum at 6 hours time point. Signals recorded are in Radiance Efficiency.

3.6 In vivo therapeutic effect
The anti-tumor activity of Mit-A nanoparticles were evaluated on the C57BL/6
orthotopic tumor-bearing mouse. Mice were treated with blank nanoparticles or Mit-A
nanoparticles every other day for 12 days (Figure 2). As shown in Figure 8F and G,
average weight of the tumor of Mit-A nanoparticles treated group was significantly less
than the control and blank nanoparticles group combined. A significant reduction in
the tumor burden was observed as compared to the blank nanoparticles group (Figure
8C) and the control group (Figure 8D). Also, there was no significant change in the
body-weight of the Mit-A nanoparticles and control group which further states that the
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biomaterials used in the nanoparticles are not toxic to the normal healthy cells present
in the colon.

Figure 8: Images of mice administered with (A) blank nanoparticles or (E) Mit-A nanoparticles in
the hydrogel. (B) Untreated tumor bearing mice. Images of tumors extracted from mice treated
with (C) blank nanoparticles or Mit-A nanoparticles (F) and untreated control tumors (D) are
shown. (G-H) Average tumor weight (G) and body weight (H) of mice treated with Mit-A
nanoparticles vs. blank nanoparticles and control group combined shown.
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3.7 Discussion
In this study, the Mit-A activity as a chemotherapeutic agent was explored by
incorporating it into nanoparticles and enhancing its activity and reducing its toxicity
by delivering the nanoparticles orally via hydrogel formulation to the intended site with
the aid of biocompatible nanomaterials. The study proved that the nanoparticles were
delivered and accumulated in the colonic region of the mouse when dispersed in
hydrogel and hydrogel remained intact at gastric pH. The hydrogel delivered the
nanoparticle payload in the colon site, which further minimized the toxicity to healthy
cells as there is no decrease in the body weight between the control and Mit-A
nanoparticle treated group. The oral formulation is known to skip the first pass
metabolism, which further reduces the hepatic toxicity caused by Mit-A. Since, Mit-A
nanoparticles also showed slow release it is expected that this will lead to a reduction
of the dosing frequency of Mit-A. Thus the results shown in this study shows that oral
administration of Mit-A nanoparticles in hydrogel using biocompatible and
biodegradable materials will actively target colon cancer and will be an efficient
nanoscale drug delivery system, which will actively target the tumor burden as well as
cancer stem cells present in the tumor mass. We also tested if the prepared
nanoparticles can target metastatic tumor by tracking the DiR nanoparticles without
hydrogel when it was delivered via Intra-Venous (IV) or Intra-Peritoneal (IP) to the
Nu/Nu nude mice and the presence of DiR nanoparticles in liver and spleen illustrates
that nanoparticles have potential to target metastatic tumor in the liver or spleen as
shown in Figure 9. These studies need further evaluation.
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Figure 9: IVIS images of mice after 3 hours post-administration of DiR nanoparticles via IP or IV. Ex-vivo
images of the same group of mice after sacrifice to confirm the presence of DiR nanoparticles in the liver,
spleen and/or lungs of mice.
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CHAPTER 4. CONCLUSION

In this study, Mit-A nanoparticles were prepared and delivered it to the colon via
hydrogel to improve Mit-A delivery to colorectal cancer. The study showed that Mit-A
nanoparticles can be delivered to colorectal cancer and exert its intended therapeutic
effect. In vivo results suggest that Mit-A nanoparticles show lower toxicity and high
efficacy in targeting CRC and CSCs. To further make the nanoparticles targeted to the
tumor site the chitosan on the outer layer of the nanoparticles can be modified with antiepithelial growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGF)
antibodies as tumors are known to overexpress EGFR and VEGF. Also, CD133, which is
a surface protein expressed in CSCs, can be used to target CSCs by modifying the outer
layer of amino groups of chitosan with anti-CD133. These nanoparticles can also be
delivered as a combination of immunotherapy and chemotherapy by dispersing the antibodies like anti-PD1 in the hydrogel with the Mit-A nanoparticles and delivering it to the
CRC. These above mentioned modifications in nanoparticles can potentially increase
therapeutic efficacy. Overall, these results lead to the conclusion that Mit-A nanoparticles
when delivered orally with hydrogel using biocompatible and biodegradable materials
targets CRC and CSCs and can be an efficient orally administered nanoscale drug
delivery system for CRC treatment.
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